▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #12 by analyst upside · 2026-09-26
BRTX
BioRestorative Therapies, Inc.
Healthcare · Market Cap $4M · P/E 0x
ANALYST PRICE TARGET
+6174.5%
implied upside to consensus target
Current Price $2.55
Consensus Target $160.0
Bull Target $300.0
Bear Target $20.0
Analysts Covering 2
ANALYST CONSENSUS - UNDERPERFORM
Strong Buy
0
Buy
0
Hold
1
Sell
1
52-Week Low $2.44
52-Week High $34.6
YTD Return +109.0%
FUNDAMENTALS
Market Cap $4M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-21.20
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.44
52-Week High $34.6
Current Price $2.55
Bear Target $20.0
Bull Target $300.0
● Now $2.55 ● Target $160.0
TRADING DATA
Avg Volume 22K
YTD Return +109.0%
Analyst Count 2
Consensus Underperform
Upside to Target +6174.5%
Last Updated 2026-09-26

ANALYST SUMMARY

BioRestorative Therapies, Inc. (BRTX) is currently trading at $2.55 with a Wall Street consensus price target of $160.0, implying potential upside of 6174.5% over the next 12 months. 2 analysts currently cover BRTX, with a consensus rating of Underperform - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $300.0, while the most cautious has a target of $20.0.

BRTX operates in the Healthcare sector with a market capitalisation of $4M. The stock is up 109.0% year-to-date and is currently trading near the lower end of its 52-week range of $2.44 – $34.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BRTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Roth MKM - Reiterated
Buy → Buy 2024-08-14 25% win rate (12 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
10
out of 100
Coverage depth
8/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →